Hosted on MSN23d
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug ... the therapy was assessed in combination with the standard-of-care atezolizumab and bevacizumab, compared to atezolizumab and ...
pharmaphorum20d
NICE says no to Keytruda in triple-negative breast cancer
Moreover, NICE says there is no data to compare Keytruda plus chemo to the combination of Roche's rival cancer immunotherapy Tecentriq (atezolizumab) and chemo – which was previously recommended ...
Yahoo Finance7d
FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA ... a single agent and in conjunction with the immune checkpoint inhibitor atezolizumab for treating ES-SCLC. ZL-1310 targets DDL3, an antigen ...
Pharmabiz7d
Genprex starts patient dosing in phase 2 expansion portion of Acclaim-3 study of Reqorsa Gene Therapy in combo with Tecentriq to treat SCLC
Genprex starts patient dosing in phase 2 expansion portion of Acclaim-3 study of Reqorsa Gene Therapy in combo with Tecentriq to treat SCLC: Austin, Texas Friday, January 24, 2025 ...
Medindia9d
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics ...